KaloBios elects Robert Baffi to board
This article was originally published in Scrip
Executive Summary
KaloBios Pharmaceuticals, a company developing a portfolio of monoclonal antibodies designed to treat severe life-threatening or debilitating diseases with a clinical focus on severe respiratory diseases and cancer, has appointed Dr Robert A Baffi to its board of directors. Dr Baffi is executive vice-president of technical operations at BioMarin Pharmaceutical.